Pharmaceutical companies use deal activity to enhance their research activities, regulatory approach, geographic presence, commercialization, and sales. The increasing development of biologics, especially in oncology, has given a significant boost to activity in recent years. Analysis suggests that while the number of deals in 2015 (until July) was lower than the number of deals in 2014, deal value in 2015 has already exceeded that of 2014.